-
![PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE](/abs-image/US/2021/12/09/US20210380609A1/abs.jpg.150x150.jpg)
公开(公告)号：US20210380609A1
公开(公告)日：2021-12-09
申请号：US17401892
申请日：2021-08-13
Applicant: Loxo Oncology, Inc. , Array BioPharma Inc.
Inventor： Charles Todd EARY , Stacey SPENCER , Zack CRANE , Katelyn CHANDO , Sylvie ASSELIN , Weidong LIU , Mike WELCH , Adam COOK , Gabrielle R. KOLAKOWSKI , Andrew T. METCALF , David A. MORENO , Tony P. TANG
IPC: C07D519/00 , C07D471/04
Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
-
![PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE](/abs-image/US/2020/10/01/US20200308194A1/abs.jpg.150x150.jpg)
公开(公告)号：US20200308194A1
公开(公告)日：2020-10-01
申请号：US16902424
申请日：2020-06-16
Applicant: Loxo Oncology, Inc. , Array BioPharma Inc.
Inventor： Charles Todd EARY , Stacey SPENCER , Zack CRANE , Katelyn CHANDO , Sylvie ASSELIN , Weidong LIU , Mike WELCH , Adam COOK , Gabrielle R. KOLAKOWSKI , Andrew T. METCALF , David A. MORENO , Tony P. TANG
IPC: C07D519/00 , C07D471/04
Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
-
公开(公告)号：US20230373999A1
公开(公告)日：2023-11-23
申请号：US18048834
申请日：2022-10-21
Applicant: MIRATI THERAPEUTICS, INC. , ARRAY BIOPHARMA INC.
Inventor： Matthew Arnold MARX , James Gail CHRISTENSEN , Christopher Ronald SMITH , James F. BLAKE , Laurence E. BURGESS , Mark Joseph CHICARELLI , Adam COOK , Jay Bradford FELL , John P. FISCHER , Macedonio J. MEJIA , Martha E. RODRIGUEZ , Pavel SAVECHENKOV , Tony P. TANG , Guy P.A. VIGERS
IPC: C07D471/04 , A61P35/00 , C07D491/08
CPC classification number: C07D471/04 , A61P35/00 , C07D491/08
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
Patent Agency Ranking
公开(公告)号：US20240101553A1
公开(公告)日：2024-03-28
申请号：US18230580
申请日：2023-08-04
Applicant: MIRATI THERAPEUTICS, INC. , ARRAY BIOPHARMA INC.
Inventor： Matthew Arnold MARX , James Gail CHRISTENSEN , Christopher Ronald SMITH , James F. BLAKE , Laurence E. BURGESS , Mark Joseph CHICARELLI , Adam COOK , Jay Bradford FELL , John P. FISCHER , Macedonio J. MEJIA , Martha E. RODRIGUEZ , Pavel SAVECHENKOV , Tony P. TANG , Guy P.A. VIGERS
IPC: C07D471/04 , A61P35/00 , C07D491/08
CPC classification number: C07D471/04 , A61P35/00 , C07D491/08
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2022/10/06/US20220313676A1/abs.jpg.150x150.jpg)
公开(公告)号：US20220313676A1
公开(公告)日：2022-10-06
申请号：US17108528
申请日：2020-12-01
Applicant: Array Biopharma Inc.
Inventor： Steven W. ANDREWS , Sean ARONOW , James F. BLAKE , Barbara J. BRANDHUBER , James COLLIER , Adam COOK , Julia HAAS , Yutong JIANG , Gabrielle R. KOLAKOWSKI , Elizabeth A. MCFADDIN , Megan L. MCKENNEY , Oren T. MCNULTY , Andrew T. METCALF , David A. MORENO , Ginelle A. RAMANN , Tony P. TANG , Li REN , Shane M. WALLS
IPC: A61K31/4545 , A61K31/4162 , C07D471/04 , A61P1/00 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/12
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2024/02/29/US20240066029A1/abs.jpg.150x150.jpg)
公开(公告)号：US20240066029A1
公开(公告)日：2024-02-29
申请号：US18342314
申请日：2023-06-27
Applicant: Array BioPharma, Inc.
Inventor： Steven W. ANDREWS , Sean ARONOW , James F. Blake , Barbara J. BRANDHUBER , Adam COOK , Julia HAAS , Yutong JIANG , Gabrielle R. KOLAKOWSKI , Elizabeth A. MCFADDIN , Megan L. MCKENNEY , Oren T. MCNULTY , Andrew T. METCALF , David A. MORENO , Tony P. TANG , Li REN
IPC: A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61P35/00 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/551
CPC classification number: A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61P35/00 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/551
Abstract: Provided herein are compounds of the Formula I:
and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2023/03/23/US20230090520A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230090520A1
公开(公告)日：2023-03-23
申请号：US17530702
申请日：2021-11-19
Applicant: Array BioPharma, Inc.
Inventor： Steven W. ANDREWS , Sean ARONOW , James F. BLAKE , Barbara J. BRANDHUBER , Adam COOK , Julia HAAS , Yutong JIANG , Gabrielle R. KOLAKOWSKI , Elizabeth A. MCFADDIN , Megan L. MCKENNEY , Oren T. MCNULTY , Andrew T. METCALF , David A. MORENO , Tony P. TANG , Li REN
IPC: A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61P35/00 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/551
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2020/01/30/US20200030311A1/abs.jpg.150x150.jpg)
公开(公告)号：US20200030311A1
公开(公告)日：2020-01-30
申请号：US16579150
申请日：2019-09-23
Applicant: Array Biopharma Inc.
Inventor： Steven W. ANDREWS , Sean ARONOW , James F. BLAKE , Barbara J. BRANDHUBER , James COLLIER , Adam COOK , Julia HAAS , Yutong JIANG , Gabrielle R. KOLAKOWSKI , Elizabeth A. McFADDIN , Megan L. McKENNEY , Oren T. McNULTY , Andrew T. METCALF , David A. MORENO , Ginelle A. RAMANN , Tony P. TANG , Li REN , Shane M. WALLS
IPC: A61K31/4545 , A61K31/4162 , C07D471/04 , A61P1/00 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/12
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.017 seconds)
